The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis

被引：40
作者：
Ding, Y. [1 ]
Sun, C. [2 ]
Li, J. [3 ]
Hu, L. [1 ]
Li, M. [1 ]
Liu, J. [1 ]
Pu, L. [4 ]
Xiong, S. [1 ]
机构：
[1] Anhui Med Univ, Dept Hematol, Hosp 2, Hematol Lab, Lotus Rd 678, Hefei 230601, Anhui, Peoples R China
[2] Anhui Med Univ, Dept Pharmacol, Hosp 2, Hefei, Anhui, Peoples R China
[3] Anhui Med Univ, Dept Emergency, Hosp 2, Hefei, Anhui, Peoples R China
[4] Third Peoples Hosp Bengbu, Dept Hematol, Bengbu, Anhui, Peoples R China
来源：
SCANDINAVIAN JOURNAL OF IMMUNOLOGY | 2017年 / 86卷 / 05期
基金：
美国国家科学基金会;
关键词：
CELL LUNG-CANCER; PD-L1; EXPRESSION; CIRCULATING PD-L1; SOLID TUMORS; SURVIVAL; LEVEL; BIOMARKER; MEMBER;
D O I：
10.1111/sji.12596
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The differential expression of soluble programmed death ligand 1 (sPD-L1) has been found in some cancers; however, the correlation between sPD-L1 expression and prognosis value in tumour is still unclear. Here, we conducted a meta-analysis and systematic review to assess the prognostic value of sPD-L1 in patients with cancer. Eligible studies were searched for in the databases including PubMed, Web of Science, ScienceDirect and Wiley Online Library database. The pooled hazard ratios (HRs) with a 95% confidence interval (95%CI) were calculated to assess the prognostic significance of sPD-L1 in human cancer. Eight studies and 1102 patients with cancer were included in the final analysis, and the combined analysis indicated that a higher level of sPD-L1 was associated with worse overall survival (OS) (HR = 1.60, 95%CI: 1.21-1.99). Furthermore, statistical significance was also observed in subgroup analysis stratified by the cancer type (haematological neoplasms or non-haematological neoplasms), sample size (more or less than 100), cut-off value of sPD-L1 (more or less than 6.51 ng/ml) and ethnicity (Asian or European). The meta-analysis indicates that circulating sPD-L1 changes may serve as a useful biomarker for cancer prognosis, and higher level of sPD-L1 may also be associated with poor outcomes in patients with cancer.
引用
收藏
页码：361 / 367
页数：7
相关论文
共 29 条
[21]   The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis [J].
Wang, A. ;
Wang, H. Y. ;
Liu, Y. ;
Zhao, M. C. ;
Zhang, H. J. ;
Lu, Z. Y. ;
Fang, Y. C. ;
Chen, X. F. ;
Liu, G. T. .
EJSO, 2015, 41 (04) :450-456
[22]   Comparative Outcome Analysis of Penicillin-Based Versus Fluoroquinolone-Based Antibiotic Therapy for Community-Acquired Pneumonia A Nationwide Population-Based Cohort Study [J].
Wang, Chi-Chuan ;
Lin, Chia-Hui ;
Lin, Kuan-Yin ;
Chuang, Yu-Chung ;
Sheng, Wang-Huei .
MEDICINE, 2016, 95 (06) :1-7
[23]   High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients [J].
Wang, Hua ;
Wang, Liang ;
Liu, Wen-Jian ;
Xia, Zhong-jun ;
Huang, Hui-Qiang ;
Jiang, Wen-Qi ;
Li, Zhi-Ming ;
Lu, Yue .
ONCOTARGET, 2016, 7 (22) :33035-33045
[24]   Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma [J].
Wang, Liang ;
Wang, Hua ;
Chen, Hao ;
Wang, Wei-da ;
Chen, Xiao-qin ;
Geng, Qi-rong ;
Xia, Zhong-jun ;
Lu, Yue .
ONCOTARGET, 2015, 6 (38) :41228-41236
[25]   PD-L1 and Survival in Solid Tumors: A Meta-Analysis [J].
Wu, Pin ;
Wu, Dang ;
Li, Lijun ;
Chai, Ying ;
Huang, Jian .
PLOS ONE, 2015, 10 (06)
[26]   Substantial contribution of extrinsic risk factors to cancer development [J].
Wu, Song ;
Powers, Scott ;
Zhu, Wei ;
Hannun, Yusuf A. .
NATURE, 2016, 529 (7584) :43-47
[27]   Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics [J].
Zhang, Jie ;
Gao, Jing ;
Li, Yanyan ;
Nie, Jun ;
Dai, Ling ;
Hu, Weiheng ;
Chen, Xiaoling ;
Han, Jindi ;
Ma, Xiangjuan ;
Tian, Guangming ;
Wu, Di ;
Shen, Lin ;
Fang, Jian .
THORACIC CANCER, 2015, 6 (04) :534-538
[28]   Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications [J].
Zheng, Zhixue ;
Bu, Zhaode ;
Liu, Xijuan ;
Zhang, Lianhai ;
Li, Ziyu ;
Wu, Aiwen ;
Wu, Xiaojiang ;
Cheng, Xiaojing ;
Xing, Xiaofang ;
Du, Hong ;
Wang, Xiaohong ;
Hu, Ying ;
Ji, Jiafu .
CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (01) :104-111
[29]   Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials [J].
Zhou, Guo-Wu ;
Xiong, Ye ;
Chen, Si ;
Xia, Fan ;
Li, Qiang ;
Hu, Jia .
MEDICINE, 2016, 95 (35)
123